| Primary |
| Hiv Infection |
72.8% |
| Product Used For Unknown Indication |
10.9% |
| Drug Use For Unknown Indication |
2.2% |
| Hypertension |
2.0% |
| Foetal Exposure During Pregnancy |
1.8% |
| Drug Exposure During Pregnancy |
1.3% |
| Depression |
0.9% |
| Antiviral Treatment |
0.9% |
| Prophylaxis Against Hiv Infection |
0.9% |
| Hepatitis |
0.8% |
| Rash |
0.8% |
| Pain |
0.7% |
| Factor Viii Deficiency |
0.7% |
| Liver Disorder |
0.6% |
| Antifungal Prophylaxis |
0.5% |
| Opportunistic Infection Prophylaxis |
0.5% |
| Tuberculosis |
0.5% |
| Prophylaxis |
0.5% |
| Acute Hiv Infection |
0.4% |
| Antiviral Prophylaxis |
0.4% |
|
| Rash |
22.4% |
| Neuropathy Peripheral |
6.0% |
| Urticaria |
6.0% |
| Off Label Use |
5.2% |
| Pyrexia |
5.2% |
| Stevens-johnson Syndrome |
5.2% |
| Rash Maculo-papular |
4.5% |
| Toxicity To Various Agents |
4.5% |
| Uveitis |
4.5% |
| Weight Increased |
4.5% |
| Liver Disorder |
3.7% |
| Myopathy |
3.7% |
| Syncope |
3.7% |
| Convulsion |
3.0% |
| Drug Exposure During Pregnancy |
3.0% |
| Drug Interaction |
3.0% |
| Hepatic Failure |
3.0% |
| Hepatitis B |
3.0% |
| Hyperlipidaemia |
3.0% |
| Hypersensitivity |
3.0% |
|
| Secondary |
| Hiv Infection |
66.0% |
| Product Used For Unknown Indication |
10.9% |
| Antiretroviral Therapy |
4.3% |
| Drug Use For Unknown Indication |
4.2% |
| Hypertension |
2.6% |
| Maternal Exposure Timing Unspecified |
2.1% |
| Antiviral Treatment |
1.8% |
| Depression |
1.1% |
| Drug Exposure During Pregnancy |
0.9% |
| Pain |
0.8% |
| Gestational Diabetes |
0.8% |
| Factor Viii Deficiency |
0.7% |
| Insomnia |
0.6% |
| Opportunistic Infection Prophylaxis |
0.5% |
| Hiv Test Positive |
0.5% |
| Chronic Obstructive Pulmonary Disease |
0.5% |
| Migraine |
0.5% |
| Antifungal Prophylaxis |
0.4% |
| Prostatomegaly |
0.4% |
| Anxiety |
0.4% |
|
| Drug Exposure During Pregnancy |
8.0% |
| Umbilical Cord Abnormality |
7.5% |
| Vitamin B12 Deficiency |
7.5% |
| Rash |
6.5% |
| Weight Increased |
6.5% |
| Premature Labour |
6.0% |
| Thrombocytopenia |
6.0% |
| Lymphadenopathy |
5.5% |
| Urinary Tract Infection |
5.5% |
| Pollakiuria |
4.5% |
| Abortion Spontaneous |
4.0% |
| Osteonecrosis |
4.0% |
| Rhabdomyolysis |
4.0% |
| Liver Disorder |
3.5% |
| Neuropathy Peripheral |
3.5% |
| Stevens-johnson Syndrome |
3.5% |
| Urticaria |
3.5% |
| Vomiting |
3.5% |
| Weight Decreased |
3.5% |
| Hypertriglyceridaemia |
3.0% |
|
| Concomitant |
| Hiv Infection |
50.3% |
| Product Used For Unknown Indication |
23.7% |
| Maternal Exposure Timing Unspecified |
4.2% |
| Drug Use For Unknown Indication |
4.1% |
| Hypertension |
2.5% |
| Drug Exposure During Pregnancy |
2.3% |
| Diabetes Mellitus |
2.0% |
| Antiretroviral Therapy |
1.6% |
| Hiv Test Positive |
1.3% |
| Hepatitis C |
1.2% |
| Depression |
1.1% |
| Burkitt's Lymphoma |
0.9% |
| Anxiety |
0.7% |
| Gestational Diabetes |
0.7% |
| Insomnia |
0.6% |
| Pain |
0.6% |
| Prophylaxis |
0.6% |
| Acne |
0.5% |
| Ear Injury |
0.5% |
| Hiv Infection Cdc Category A3 |
0.5% |
|
| Renal Failure Acute |
8.2% |
| Thrombocytopenia |
8.2% |
| Myocardial Infarction |
7.4% |
| Premature Baby |
7.4% |
| Weight Decreased |
7.4% |
| Abortion Spontaneous |
6.6% |
| Weight Increased |
6.6% |
| Umbilical Cord Abnormality |
5.7% |
| Vomiting |
5.7% |
| B-cell Lymphoma |
4.1% |
| Renal Colic |
4.1% |
| Death |
3.3% |
| Foetal Exposure During Pregnancy |
3.3% |
| Hypokalaemia |
3.3% |
| Premature Labour |
3.3% |
| Rectal Cancer |
3.3% |
| Rhabdomyolysis |
3.3% |
| Ventricular Extrasystoles |
3.3% |
| Virologic Failure |
3.3% |
| Abdominal Pain |
2.5% |
|
| Interacting |
| Hiv Infection |
66.0% |
| Pulmonary Arterial Hypertension |
8.0% |
| Product Used For Unknown Indication |
6.0% |
| Blood Cholesterol Increased |
4.0% |
| Hyperphosphataemia |
4.0% |
| Hypertension |
4.0% |
| Depression |
2.0% |
| Herpes Simplex |
2.0% |
| Hiv Test Positive |
2.0% |
| Oesophagitis |
2.0% |
|
| Drug Interaction |
15.4% |
| Neuropathy Peripheral |
15.4% |
| Drug-induced Liver Injury |
7.7% |
| Hepatotoxicity |
7.7% |
| Hyperglycaemia |
7.7% |
| Pancreatitis Acute |
7.7% |
| Potentiating Drug Interaction |
7.7% |
| Pulmonary Arterial Hypertension |
7.7% |
| Pulmonary Hypertension |
7.7% |
| Red Blood Cell Count Abnormal |
7.7% |
| Renal Impairment |
7.7% |
|
